"With DeSci, you can bypass Big Pharma and these massive gatekeepers that sometimes stop science from happening, and stop science from making new inventions and drugs that could really impact the world in a good way," BIO protocol founder Paul Kohlhaas said.
"Looking forward, if the economy evolves broadly as expected, policy will move over time toward a more neutral stance. But we are not on any preset course," Powell said.
"This is not a committee that feels like it's in a hurry to cut rates quickly," he continued.
Most of that flow went into BlackRock's IBIT, which currently leads in net inflow since its inception at $21.5 billion.
Collection
[
|
...
]